VEGPF News Alert Vectura Group Plc (VEGPF) 2.1000 09/20/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Vectura Group Plc (VEGPF) 2.1000 $VEGPF

Global Chronic Cough Therapeutics Pipeline Review 2014 - 7 Companies & 7 Drug Profiles
M2 - Tue Sep 16, 8:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hx29h3/chronic_cough) has announced the addition of the "Chronic Cough - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Cough, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Cough and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Vectura Group plc - Glenmark Pharmaceuticals Ltd. - OPKO Health, Inc. - Afferent Pharmaceuticals, Inc. - Cerecor Inc. - Ario Pharma Ltd Drug Profiles - SCH-900978 - XEND-0501 - AF-219 - GRC-17536 - memantine hydrochloride - GSK-2339345 - VR-611 For more information visit http://www.researchandmarkets.com/research/hx...onic_cough

Lung Transplantation - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/lhlntx/lung) has announced the addition of the "Lung Transplantation - Pipeline Review, H1 2014" report to their offering. 'Lung Transplantation - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lung Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Transplantation. Scope - A snapshot of the global therapeutic scenario for Lung Transplantation. - A review of the Lung Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lung Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Lung Transplantation Overview Therapeutics Development Pipeline Products for Lung Transplantation - Overview Pipeline Products for Lung Transplantation - Comparative Analysis Lung Transplantation - Therapeutics under Development by Companies Lung Transplantation - Pipeline Products Glance Late Stage Products Early Stage Products Lung Transplantation - Companies Involved in Therapeutics Development Lung Transplantation - Therapeutics Assessment Drug Profiles cyclosporine - Drug Profile EZ-2053 - Drug Profile Elafin - Drug Profile Respiratory and Inflammatory Diseases Program - Drug Profile VR-909 - Drug Profile Lung Transplantation - Recent Pipeline Updates Lung Transplantation - Product Development Milestones Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Quark Pharmaceuticals, Inc. Vectura Group plc Proteo, Inc. APT Pharmaceuticals, Inc. (Inactive) Neopharm Ltd. For more information visit http://www.researchandmarkets.com/research/lhlntx/lung About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Global Erectile Dysfunction Clinical Trials Review Report, H2 2013
M2 - Thu Jan 09, 10:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/mpz4sf/erectile) has announced the addition of the "Erectile Dysfunction Global Clinical Trials Review, H2, 2013" report to their offering. This report provides elemental information and data relating to the clinical trials on Erectile Dysfunction. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Erectile Dysfunction. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Bayer AG - Pfizer Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Vivus, Inc. - Johnson & Johnson - SK Chemicals Co., Ltd. - Dong-A Socio Holdings Co Ltd - Warner Chilcott Plc - Vectura Group plc For more information visit http://www.researchandmarkets.com/research/mpz4sf/erectile

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w94m9s/chronic) has announced the addition of the "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2013" report to their offering. 'Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD). Scope - A snapshot of the global therapeutic scenario for Chronic Obstructive Pulmonary Disease (COPD). - A review of the Chronic Obstructive Pulmonary Disease (COPD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Chronic Obstructive Pulmonary Disease (COPD) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Johnson & Johnson Boehringer Ingelheim GmbH Kyowa Hakko Kirin Co., Ltd. Osiris Therapeutics, Inc. EpiGenesis Pharmaceuticals, Inc. Amgen Inc. AstraZeneca PLC GlaxoSmithKline plc MedImmune LLC Merck & Co., Inc. Dainippon Sumitomo Pharma Co., Ltd. Bioneer Corporation Vectura Group plc Pearl Therapeutics, Inc. Nycomed International Management GmbH Novartis AG ASKA Pharmaceutical Co., Ltd Chiesi Farmaceutici SpA Dong-A Pharmaceutical Co., Ltd. Glenmark Pharmaceuticals Ltd. Kissei Pharmaceutical Co., Ltd. Laboratoires Pierre Fabre SA Meda AB Orion Corporation and many more... For more information visit http://www.researchandmarkets.com/research/w94m9s/chronic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Transplantation - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s2563g/transplantation) has announced the addition of the "Transplantation - Pipeline Review, H2 2013" report to their offering. 'Transplantation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Transplantation. Scope - A snapshot of the global therapeutic scenario for Transplantation. - A review of the Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Hospira, Inc. F. Hoffmann-La Roche Ltd. Kyowa Hakko Kirin Co., Ltd. Osiris Therapeutics, Inc. Athersys, Inc. GlaxoSmithKline plc Quark Pharmaceuticals, Inc. Merck & Co., Inc. AbGenomics International, Inc. Emergent BioSolutions Inc. Oxford BioMedica plc Pharming Group N.V. Vectura Group plc BioLineRx, Ltd. Novartis AG Isotechnika Pharma Inc. Samyang Corporation Astellas Pharma Inc. ViroPharma Incorporated Cell Therapeutics, Inc. Genmab A/S Exelixis, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/s2...plantation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Global Pulmonary Drug Delivery Systems Market 2012-2016: Intense Competition a Major Challenge Faced By the Market
M2 - Tue Jul 30, 6:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mf9vgx/global_pulmonary) has announced the addition of the "Global Pulmonary Drug Delivery Systems Market 2012-2016" report to their offering. The analysts forecast the Global Pulmonary Drug Delivery Systems market to grow at a CAGR of 14.47 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing incidence of lung-related or respiratory diseases. The Global Pulmonary Drug Delivery Systems market has also been witnessing an increasing adoption of online marketing strategy. However, intense competition among vendors could pose a challenge to the growth of this market. Commenting on the report, an analyst from the team said: The Global Pulmonary Drug Delivery Systems market is highly fragmented with a large number of vendors having significant market shares. These vendors range from large corporations producing a broad range of advanced and premium pulmonary drug delivery systems on a worldwide scale to small and medium-sized companies that concentrate on a single product line in a specific geographic region. Further, there is strong competition from cheaper private label products also. The leading vendors are presently working on low profit because of strong competition. Moreover, there is severe pricing pressure, which leads to a reduction in vendors' profit margins. Thus, intense competition is a major challenge faced by the market, and it is expected to pose a strong challenge to the market growth during the forecast period. According to the report, one of the major drivers is the increasing prevalence of lung-related or respiratory diseases such as asthma and COPD across the globe. It is estimated that around 300 million people are suffering from asthma. This influences the market for pulmonary drug delivery inhalation devices. Companies Mentioned - 3M Healthcare Ltd. - Akela Pharma Inc. - Alkermes Inc. - Allied Healthcare Products Inc. - AstraZeneca plc - Boehringer Ingelheim GmbH - CareFusion Corp. - Chiesi Farmaceutici S.p.A. - Dainippon Sumitomo Pharma Co. Ltd. - GF Health Products Inc. - GlaxoSmithKline plc - Novartis AG - Omron Healthcare Co. Ltd. - PARI Respiratory Equipment Inc. - Philips Respironics Inc. - SkyePharma plc - Sunovion Pharmaceuticals Inc. - Vectura Group plc. For more information visit http://www.researchandmarkets.com/research/mf..._pulmonary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Lung Transplantation - Pipeline Review, H1 2013
M2 - Fri Apr 12, 5:28AM CDT
Research and Markets has announced the addition of the "Lung Transplantation - Pipeline Review, H1 2013" report to their offering. 'Lung Transplantation - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lung Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Transplantation. Scope - A snapshot of the global therapeutic scenario for Lung Transplantation. - A review of the Lung Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lung Transpl

Erectile Dysfunction - Pipeline Review, H1 2013
M2 - Mon Mar 25, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hp2gn2/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Erectile Dysfunction - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Erectile Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Erectile Dysfunction. Scope - A snapshot of the global therapeutic scenario for Erectile Dysfunction. - A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline proje

Premature Ejaculation - Pipeline Review, H1 2013
M2 - Thu Mar 21, 3:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tpptkh/premature) has announced the addition of the "Premature Ejaculation - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Premature Ejaculation - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Premature Ejaculation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Premature Ejaculation. Scope - A snapshot of the global therapeutic scenario for Premature Ejaculation. - A review of the Premature Ejaculation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipelin

Migraine - Pipeline Review, H1 2013
M2 - Tue Mar 12, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wqgjw4/migraine) has announced the addition of Global Markets Direct's new report "Migraine - Pipeline Review, H1 2013" to their offering. Global Markets Direct's, 'Migraine - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Migraine, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Migraine. Migraine - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Migraine. - A review of the Mi

Cystic Fibrosis - Pipeline Review, H2 2012
M2 - Tue Jan 08, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/p9x3z6/cystic_fibrosis) has announced the addition of Global Markets Direct's new report "Cystic Fibrosis - Pipeline Review, H2 2012" to their offering. 'Cystic Fibrosis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cystic Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cystic Fibrosis. Scope - A snapshot of the global therapeutic scenario for Cystic Fibrosis. - A review of the Cystic Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monothe




Scroll down for more posts ▼

Top 10 Most Recent News Articles

NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 132

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
Ampace Targets AI Data Centre UPS Safety Needs in Paris

Updated Category News Views 94

Backup power gets interesting only after the grid has disappointed everybody. At Data Centre World Paris 2026, Ampace put its attention on that ugly, split-second handoff: utility power drops, a UPS has to catch the load immediately, and nobody operating an AI data centre gets to shrug if it does not. A Narrow Job With Brutal Consequences The company showcased its PU200...

Continue Reading
Nvidia Lawsuit Allegations Put Disclosure Risk in Focus

Updated Category News Views 83

A lawsuit notice can turn a roaring chip story sour in a hurry, and this one deserves a cold, careful read rather than the usual internet stampede. DJS Law Group says it has filed a securities class action against NVIDIA, alleging that the company made materially false and misleading statements during a stated class period running from October 9, 2025 through November 8,...

Continue Reading
Birla Carbon's Rayong Bet Tightens Asian Supply Lines

Updated Category News Views 130

Rayong just became a much louder pin on Asia's industrial map. Birla Carbon has inaugurated a 120 kMT carbon black plant in Thailand, and the significance is bigger than a ribbon-cutting photo. This is a capacity-and-location move aimed squarely at the uncomfortable part of industrial supply chains: customers need material when they need it, not after it has spent weeks...

Continue Reading
Prospera’s DFW Culture Win Matters Beyond the Plaque

Updated Category News Views 46

Employee survey ballots rarely make pulses race, but this one deserves more than a lazy shrug. Prospera Financial Services has landed on The Dallas Morning News’ 2026 Top Workplaces DFW list for a second consecutive year, placing in the Top Small Workplaces category. For a boutique independent broker-dealer, that is not meaningless wall décor. The people doing the...

Continue Reading
Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 29

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading
Trade Secret Damages Turn on Corporate Intent Evidence

Updated Category News Views 72

Suspicion may rattle a courtroom, but it apparently does not always loosen the jury’s purse strings. That is the useful, slightly sobering takeaway from DOAR’s new national study on damages in trade secret disputes, released November 20, 2026. Jurors, according to the report, draw a meaningful line between an employee carrying experience to a new job and a company...

Continue Reading
Epiroc Takes Live Remote Drilling to CES 2027 Stage

Updated Category News Views 0

A drill rig chewing through Virginia rock from a Las Vegas convention booth is either a serious industrial-tech moment or an expensive magic trick. At CES 2027, Epiroc intends to make the distinction painfully clear. From January 6 through 9, the Stockholm-based mining-equipment company and Luck Stone will connect Booth 7031 in the LVCC West Hall to a working quarry in...

Continue Reading
Nansha's Trade Pitch Has Numbers, but Questions Remain

Updated Category News Views 10

A Chilean cherry spending 22 days at sea can tell an investor plenty about where Guangzhou's Nansha District wants to sit in Asia-Pacific commerce. Not glamorous, no. But trade infrastructure rarely is until volumes pile up, routes deepen, and somebody else finds they cannot easily replicate the network. Nansha is using the expected 33rd APEC Economic Leaders' Meeting in...

Continue Reading
Home Nursing Plans Need Clarity Before the Next Crisis

Updated Category News Views 50

A medication change scribbled on a loose sheet can become a very long night. That is the unglamorous truth behind the discussion from Michael and Marsha Reda of Aurora Home Care in Williamsville, New York: long-term home nursing care depends on a plan people can actually follow when the household is tired, worried, and juggling too much. Their perspective, featured by...

Continue Reading

Top 5 Most Recently Viewed Articles

Ragie Launches Advanced Agent Ready Features for Developers

Updated Category News Views 253

Ragie Introduces Innovative Agent Ready Features Ragie is excited to present its latest advancement: the introduction of Agent Ready capabilities. This launch focuses on empowering developers with tools for creating intelligent, context-aware agents. Enhanced features like Agentic Retrieval and support for Right-to-Left (RTL) languages enhance accessibility and robust...

Continue Reading
JNR Stellarc 100K: A Game-Changer in Refillable Vapes

Updated Category News Views 200

Introducing the JNR Stellarc 100K Refillable Vape JNR has officially launched the JNR Stellarc 100K, a remarkable modular refillable vape system that promises to redefine the vaping experience. Engineered for extreme endurance and superior safety features, the Stellarc 100K is set to offer unparalleled value to its users. This advanced vape is not just another product; it...

Continue Reading
Xiao-I Corporation Shareholders Encouraged to Join Class Action

Updated Category News Views 86

Xiao-I Corporation Shareholders Encouraged to Join Class Action Recent events have led to significant concerns for shareholders of Xiao-I Corporation. With allegations of misleading statements and inadequate disclosures surfacing, many shareholders find themselves at a crossroads. It is essential for investors who purchased shares during a specific period to explore their...

Continue Reading
Assessing Bristol Myers Squibb: Analyst Insights and Future Prospects

Updated Category News Views 138

Bristol Myers Squibb: A Low Valuation Opportunity BofA Securities has recently upgraded Bristol Myers Squibb Co. (NYSE: BMY) from a Neutral position to a Buy rating, indicating a positive outlook for the company driven by strong near-term catalysts. Analyst Jason Gerberry highlighted a compelling risk-reward scenario, especially as the company anticipates a flat...

Continue Reading
Carrier's Q3 Performance and Future Outlook: Key Insights

Updated Category News Views 237

Carrier Global Corporation's Q3 Earnings Overview Carrier Global Corporation (NYSE: CARR), a prominent innovator in climate and energy solutions, recently released its third-quarter earnings, showcasing performance that exceeded market expectations. The results highlight not only the financial stability of the company but also the strategic adjustments made to navigate...

Continue Reading